Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Daniel B. Levine is of counsel in the firm’s Shanghai office and a member of the Mergers and Acquisitions Practice Group. He advises public and private companies and investment funds in inbound and outbound mergers and acquisitions, joint ventures, venture capital investments, technology and licensing transactions, and other transactional matters. Mr. Levine has represented clients in a wide range of industries and has extensive experience in the life sciences sector in China, having represented global pharma and medical device companies, clinical-stage companies, and life sciences investment funds in cross-border product acquisitions and divestitures, financings, joint ventures, collaborations, licensing transactions, and co-promotion and distribution agreements.

  • JW Therapeutics in its purchase of substantially all of the assets of Syracuse Biopharma, a spin-out of Eureka Therapeutics.
  • A global pharma company in its formation of a Hong Kong joint venture with a leading Asia-based private equity firm.
  • Hua Medtech in its sale to Genesis Medtech.
  • A leading life sciences company in a corporate venture investment in a China-based diagnostics and testing business.
  • LONGi Green Energy Technology Co. Ltd. in its acquisition of a Malaysian manufacturing facility from and commercial agreements with SunEdison.
  • Origin Technologies Corporation, LLC in connection with its $1.8 billion bid for Affymetrix, Inc.
  • A leading Chinese technology company in multiple corporate venture capital transactions.
  • AstraZeneca in a strategic alliance with WuXi Apptec, including an option to acquire a biologics manufacturing facility in Wuxi City.
  • A leading multinational pharma company in an option to acquire, and a minority investment in, a China-based innovative and pharma company.
  • Huadong Pharmaceutical in an exclusive license to develop, manufacture, and commercialize a diabetes product from vTv Therapeutics.
  • Cathay Pacific in the negotiation of a long-term distribution agreement with a leading GDS.
  • A specialty healthcare company in its licensing of marketing rights for OTC consumer drugs.
  • Telular Corporation in its sale to Avista Capital Partners for $253 million.
  • Illumina, Inc. in its acquisition of Verinata Health, Inc. for up to $450 million in upfront and contingent payments.
  • MidFirst Bank in its acquisition of Presidential Financial Corporation from Harbert Private Equity and the Belfer family.
  • One Equity Partners in its minority investment in Grupo Phoenix, a leading packaging company in the Americas.
  • A leading private equity fund in the formation of the largest veterinary products company in the United States and the subsequent sale of the fund’s interest therein.
  • A leading middle-market private equity fund in the initial and add-on acquisitions forming the largest integrated retail property services firm in North America.

Pro Bono

  • Assisted Dr. Sumanth Kaja and other Emergency Medicine Resident Physicians at Bellevue and NYU Langone Hospital to procure N95 respirators and other PPE from China.

Previous Experience

  • Bear, Stearns & Co., Inc., Financial Analytics and Structured Transactions Group and Corporate Finance Department (1997-2001)
  • New York Super Lawyers, Mergers & Acquisitions "Rising Star" (2013)